| Literature DB >> 35181720 |
Jonás Carmona-Pírez1,2,3, Antonio Gimeno-Miguel4,5, Kevin Bliek-Bueno4,6, Beatriz Poblador-Plou4,5, Jesús Díez-Manglano4,7, Ignatios Ioakeim-Skoufa4,8,9,10, Francisca González-Rubio4,5,11,10, Antonio Poncel-Falcó4,5,12, Alexandra Prados-Torres4,5, Luis A Gimeno-Feliu4,5,13.
Abstract
A major risk factor of COVID-19 severity is the patient's health status at the time of the infection. Numerous studies focused on specific chronic diseases and identified conditions, mainly cardiovascular ones, associated with poor prognosis. However, chronic diseases tend to cluster into patterns, each with its particular repercussions on the clinical outcome of infected patients. Network analysis in our population revealed that not all cardiovascular patterns have the same risk of COVID-19 hospitalization or mortality and that this risk depends on the pattern of multimorbidity, besides age and sex. We evidenced that negative outcomes were strongly related to patterns in which diabetes and obesity stood out in older women and men, respectively. In younger adults, anxiety was another disease that increased the risk of severity, most notably when combined with menstrual disorders in women or atopic dermatitis in men. These results have relevant implications for organizational, preventive, and clinical actions to help meet the needs of COVID-19 patients.Entities:
Mesh:
Year: 2022 PMID: 35181720 PMCID: PMC8857317 DOI: 10.1038/s41598-022-06838-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographic and clinical characteristics of individuals aged 15 years or older with COVID-19 infection in the PRECOVID Cohort.
| Characteristics | Total (N = 48,415) | Men (N = 20,936) | Women (N = 27,479) |
|---|---|---|---|
| Mean age (sd) | 52.0 (21.10) | 51.7 (20.47) | 52.3 (21.56) |
| 15–64 years | 35,106 (72.5%) | 15,279 (73.0%) | 19,827 (72.2%) |
| 65–79 years | 6,961 (14.4%) | 3,431 (16.4%) | 3,530 (12.8%) |
| ≥ 80 years | 6,348 (13.1%) | 2,226 (10.6%) | 4,122 (15.0%) |
| Mean number of chronic diseases (sd) | 3.94 (2.88) | 3.50 (2.61) | 4.29 (3.02) |
| Total | 38,323 (79.2%) | 15,659 (74.8%) | 22,664 (82.5%) |
| 15–64 years | 25,605 (72.9%) | 10,306 (67.5%) | 15,299 (77.2%) |
| 65–79 years | 6,568 (94.4%) | 3,190 (93.0%) | 3,378 (95.7%) |
| ≥ 80 years | 6,150 (96.9%) | 2,163 (97.2%) | 3,987 (96.7%) |
| Outcomes | |||
| Hospitalization (N, %) | 4,586 (9.5%) | 2,400 (11.5%) | 2,186 (8.0%) |
| 30-day-mortality (N, %) | 1,311 (2.7%) | 683 (3.3%) | 628 (2.3%) |
| Total | 5,117 (10.6%) | 2,671 (12.8%) | 2,446 (8.9%) |
| 15–64 years | 1,572 (4.5%) | 903 (5.9%) | 669 (3.4%) |
| 65–79 years | 1,338 (19.2%) | 790 (23.0%) | 548 (15.5%) |
| ≥ 80 years | 2,207 (34.8%) | 978 (43.9%) | 1,229 (29.8%) |
† Multimorbidity, defined as the simultaneous co-existence of two or more chronic diseases, excluding COVID-19; sd, standard deviation; †† Severity, defined as a composite outcome based on the need for hospital admission (including in Intensive Care Units) or 30-day all-cause mortality.
Figure 1Disease composition of the multimorbidity patterns identified in the study population based on sex and age, accordign to prevalence (proportional to node size) and observed/expected prevalence ratios (O/E PRs). A disease was included as a part of a pattern when presented a prevalence greater than 25% and/or a O/E PR ≥ 2 (witha prevalence of at least 1%). In broken lines patterns with statistically significant age-adjusted odds ratios of infection severity.
Denomination and prevalence of multimorbidity patterns found in COVID-19 patients based on sex and age and their age-adjusted odds ratios (aOR) of infection severity compared with chronic patients without multimorbidity.
| 15–64 years | 65–79 years | ≥ 80 years | ||||
|---|---|---|---|---|---|---|
| Pattern name (N, prevalence %) | Severity aOR (95% CI) | Pattern name (N, prevalence %) | Severity aOR (95% CI) | Pattern name (N, prevalence %) | Severity aOR (95% CI) | |
| Cardiometabolic (541, 13.1%) | 1.29 (0.85–1.96) | |||||
| Thyroid-cardiometabolic (515, 14.6%) (no diabetes mellitus) | 1.55 (0.86–2.79) | Psychogeriatric (1,011, 24.5%) | 1.06 (0.71–1.58) | |||
| Mental health (2,046, 10.3%) | 0.90 (0.63–1.29) | Osteoporotic-cardiovascular (70, 19.9%) (no diabetes mellitus) | 1.20 (0.67–2.14) | Mental health (753, 18.3%) | 1.32 (0.87–1.98) | |
| Upper respiratory (1,987, 10.0%) | 1.13 (0.79–1.62) | Mental health (823, 23.3%) (no diabetes mellitus) | 1.58 (0.90–2.80) | Non-specific (1,679, 40.8%) | 1.05 (0.71–1.55) | |
| Non-specific (663, 18.8%) (no diabetes mellitus) | 1.22 (0.68.2.18) | |||||
| Control group (4,528, 22.8%) | Control group (152, 4.3%) | Control group (135, 3.3%) | ||||
| Cardiometabolic I (546, 24.6%) | 1.28 (0.96–1.70) | |||||
| Cardiometabolic II (619, 18.1%) (no obesity) | 1.23 (0.84–1.81) | Cardiometabolic II (590, 26.5%) | 1.28 (0.96–1.70) | |||
| Cardiometabolic III (637, 18.6%) (no obesity) | 1.41 (0.96–2.06) | Arthrosis-cardiometabolic (444, 20.0%) | 1.28 (0.96–1.71) | |||
| Upper respiratory (1,446, 9.5%) | 1.30 (0.97–1.75) | Prostatic-cardiometabolic (699, 20.4%) (18% obesity) | 1.30 (0.89–1.89) | Prostatic (233, 10.5%) | 1.30 (0.92–1.84) | |
| Headache (1,949, 12.8%) | 1.24 (0.93–1.64) | Arthrosis-cardiometabolic (394, 11.5%) (no obesity) | 1.20 (0.80–1.82) | |||
| Non-specific (416, 12.1%) (no obesity) | 1.28 (0.85–1.93) | |||||
| Control group (4,973, 32.6%) | Control group (241, 7.0%) | Control group (63, 2.8%) | ||||
In bold letters, patterns with statistically significant age-adjusted odds ratios of infection severity; Control group: chronic patients without multimorbidity; CI: confidence interval.